↑"Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials". The Lancet. Neurology23 (11): 1119–1132. November 2024. doi:10.1016/S1474-4422(24)00328-4. PMID39307151.